Volume 116, Issue 3 , Pages 643-649, September 2005
Multicenter study of emergency department visits for insect sting allergies
Background
An earlier study of food-related anaphylaxis in the emergency department (ED) suggested low concordance with national guidelines for anaphylaxis management.
Objective
To extend these findings, we performed a chart review study to describe current ED management of insect sting allergy.
Methods
The Multicenter Airway Research Collaboration performed a chart review study in 15 North American EDs. Investigators reviewed 617 charts of patients with insect sting allergy. Patients were identified by using International Classification of Diseases, 9th Revision, codes 989.5 (toxic effect of venom), 995.0 (other anaphylactic shock), and 995.3 (allergy, unspecified).
Results
The cohort was 42% female and 61% white, with a mean age of 36 ± 19 years. In this cohort, 58% had local reactions, 11% had mild systemic reactions, and 31% had anaphylactic reactions, as defined by multisystem organ involvement or hypotension. Among patients with systemic reactions (mild or anaphylaxis), most (75%) were stung within 6 hours of ED arrival. While in the ED, 69% of systemic reaction patients received antihistamines, 50% systemic corticosteroids, and 12% epinephrine. Almost all systemic reaction patients (95%) were discharged to home. At ED discharge, 27% (95% CI, 22% to 33%) of systemic reaction patients received a prescription for self-injectable epinephrine. Only 20% (95% CI, 15% to 26%) had documentation of referral to an allergist.
Conclusions
Although guidelines suggest specific approaches for the emergency management of insect sting allergy, concordance with these guidelines appears low in patients with a severe insect sting reaction.
Key words: Insect sting allergy, emergency department, epinephrine, referral to allergist
Abbreviations used: ED, Emergency department, IQR, Interquartile range
Disclosure of potential conflict of interest: A. Long has consulted with AstraZeneca, Schering Plough, and Altana, and is on the speakers' bureau of Genentech, Novartis, GlaxoSmithKline, Pfizer, Schering Plough, and Sanofi-Aventis. C. Camargo has a consulting arrangement with Dey and Verus and receives grants and research money from Dey. There are no other conflicts of interest to disclose.Ms Clark is supported by grant T32 ES07069 from the National Institute of Environmental Health Services (Research Triangle Park, NC) and Dr Camargo by grant AI52338 from the National Institute of Allergy and Infectious Disease (Bethesda, Md). The project was supported by unrestricted grants from Dey Laboratories (Napa, Calif) and the Food Allergy and Anaphylaxis Network (Fairfax, Va).
PII: S0091-6749(05)01526-5
doi:10.1016/j.jaci.2005.06.026
© 2005 American Academy of Allergy, Asthma and Immunology. Published by Elsevier Inc. All rights reserved.
Volume 116, Issue 3 , Pages 643-649, September 2005
